Luis Antonio Corchete Sánchez
Has grant
Associate member
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Role of sex chromosomes in multiple myeloma
Open Date: 2024-01-01
Close Date:
Grant: Close
Investigación del splicing del RNA y de su regulación en el mieloma múltiple
Open Date: 2016-01-01
Close Date: 2018-01-01
Articles (17)
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
In the last few years, nivolumab has become the standard of care for advanced-stage lung cancer patients. Unfortunately, up to 60% of patients do not respond to this treatment. In our study, we identified variations in gene expression related to primary resistance to immunotherapy. Bronchoscopy biopsies were obtained from advanced non-small cell lung cancer (NSCLC) patients previously characterized as responders or non-responders after nivolumab treatment. Ten tumor biopsies (from three responders and seven non-responders) were analyzed by the differential expression of 760 genes using the NanoString nCounter platform. These genes are known to be involved in the response to anti-PD1/PD-L1 therapy. All the patients were treated with nivolumab. Examining the dysregulated expression of 24 genes made it possible to predict the response to nivolumab treatment. Supervised analysis of the gene expression profile (GEP) revealed that responder patients had significantly higher levels of expression of CXCL11, NT5E, KLRK1, CD3G, GZMA, IDO1, LCK, CXCL9, GNLY, ITGAL, HLA-DRB1, CXCR6, IFNG, CD8A, ITK, B2M, HLA-B, and HLA-A than did non-responder patients. In contrast, PNOC, CD19, TP73, ARG1, FCRL2, and PTGER1 genes had significantly lower expression levels than non-responder patients. These findings were validated as predictive biomarkers in an independent series of 201 patients treated with nivolumab (22 hepatocellular carcinomas, 14 non-squamous cell lung carcinomas, 5 head and neck squamous cell carcinomas, 1 ureter/renal pelvis carcinoma, 120 melanomas, 4 bladder carcinomas, 31 renal cell carcinomas, and 4 squamous cell lung carcinomas). ROC curve analysis showed that the expression levels of ITK, NT5E, ITGAL, and CD8A were the best predictors of response to nivolumab. Further, 13/24 genes showed an adverse impact on overall survival (OS) in an independent, large series of patients with NSCLC (2166 cases). In summary, we found a strong association between the global GEP of advanced NSCLC and the response to nivolumab. The classification of NSCLC patients based on GEP enabled us to identify those patients who genuinely benefited from treatment with immune checkpoint inhibitors (ICIs). We also demonstrated that abnormal expression of most of the markers comprising the genomic signature has an adverse influence on OS, making them significant markers for therapeutic decision-making. Additional prospective studies in larger series of patients are required to confirm the clinical utility of these biomarkers.
Year:
2024
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients’ samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Collaborators (24)
María Dolores Ludeña
Catedrático de Universidad
University Hospital of Salamanca
Claire Palles
Associate Professor
University of Birmingham
Elena Bueno Martínez
Profesora Ayudante Doctora
Universidad de Valladolid
Cristina Carbonell
Profesora asociada en Ciencias de la Salud
Universidad de Salamanca
Silvio Ragozzino
University Hospital Basel
José Perea
-
Gema Santamaría
Professor
Universidad de Valladolid
Jesús Seco-Calvo
Catedrático e investigador principal
Universidad de León
Teresa Paíno
Universidad de Salamanca
Alexandra Bacquelaine Veloso
Team Leader
University of Liege
Yun Wei
Assistant Professor
University of Texas Southwestern Medical Center
Miguel Marcos
Catedrático de Universidad con plaza vinculada
Universidad de Salamanca
Fermin Sanchez-Guijo
Full-Professor of Medicine (Catedrático de Medicina)
Universidad de Salamanca
Francesc Balaguer
Associate Professor
University of Barcelona
Esther Rheinbay
Massachusetts General Hospital
Alberto Orfao
-
Maartje Nielsen
Clinical geneticist
Leiden University Medical Center
Mercedes Garayoa
Instituto de Investigación Biomédica de Málaga
Enrique M. Ocio
Head of the Department
Marqués de Valdecilla University Hospital
Roberto Corchado Cobos
-
Jose Maria sayagues
Universidad de Salamanca
Antonino Spinelli
Full Professor od Surgery
Humanitas University
Julia Almeida
Full Proffesor
Universidad de Salamanca
Rogelio González-Sarmiento
Catedrático
Universidad de Salamanca
Make your next move.
Prepare your application
Review drafts before you send them.